POSB50 A Cost-Effectiveness Analysis of Rivaroxaban in Combination with Acetylsalicylic Acid (ASA) in Adult Patients with Coronary Artery Disease (CAD) or Symptomatic Peripheral Artery Disease (PAD) at High Risk of Ischaemic Events

Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.323
https://www.valueinhealthjournal.com/article/S1098-3015(21)02118-5/fulltext
Section Title :
Section Order : 11094
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02118-5&doi=10.1016/j.jval.2021.11.323
HEOR Topics :
Tags :
Regions :